Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Revenue of $136.0 million for Q1 2026, down 2.16% year-over-year from $139.0 million in Q1 2025, and down 34.39% quarter-over-quarter from $207.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Revenue for 11 consecutive years, with $136.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 2.16% year-over-year to $136.0 million; the TTM figure through Mar 2026 stood at $669.7 million (up 13.48% YoY), while the FY2025 annual figure was $673.0 million, up 20.18% from the prior year.
- Revenue slipped to $136.0 million in Q1 2026 per RARE's latest filing, from $207.3 million in the prior quarter.
- Across five years, Revenue topped out at $207.3 million in Q4 2025 and bottomed at $79.9 million in Q1 2022.
- Historically, Revenue has averaged $127.4 million across 5 years, with a median of $127.1 million in 2023.
- Annual changes were most pronounced in 2022 — Revenue declined 19.58% — and 2024, when it jumped 42.27%.
- Ultragenyx Pharmaceutical's Revenue stood at $103.3 million in 2022, then climbed by 23.02% to $127.1 million in 2023, then advanced by 29.5% to $164.6 million in 2024, then rose by 25.89% to $207.3 million in 2025, then sank by 34.39% to $136.0 million in 2026.
- Business Quant data shows RARE's Revenue at $136.0 million in Q1 2026, $207.3 million in Q4 2025, and $159.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 214.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 214.00 Mn |
| Mar 31, 2026 | 136.00 Mn |
| Dec 31, 2025 | 207.28 Mn |
| Sep 30, 2025 | 159.93 Mn |
| Jun 30, 2025 | 166.50 Mn |
| Mar 31, 2025 | 139.00 Mn |
| Dec 31, 2024 | 164.65 Mn |
| Sep 30, 2024 | 139.49 Mn |
| Jun 30, 2024 | 147.03 Mn |
| Mar 31, 2024 | 108.83 Mn |
| Dec 31, 2023 | 127.14 Mn |
| Sep 30, 2023 | 98.05 Mn |
| Jun 30, 2023 | 108.31 Mn |
| Mar 31, 2023 | 100.50 Mn |
| Dec 31, 2022 | 103.35 Mn |
| Sep 30, 2022 | 90.70 Mn |
| Jun 30, 2022 | 89.34 Mn |
| Mar 31, 2022 | 79.94 Mn |
| Dec 31, 2021 | 83.39 Mn |
| Sep 30, 2021 | 81.65 Mn |